Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Lett ; 265(1): 135-47, 2008 Jun 28.
Article in English | MEDLINE | ID: mdl-18353537

ABSTRACT

The carcinogenic effects of individual polycyclic aromatic hydrocarbons (PAH) are well established. However, their potency within an environmental complex mixture is uncertain. We evaluated the influence of diesel exhaust particulate matter on PAH-induced cytochrome P450 (CYP) activity, PAH-DNA adduct formation, expression of certain candidate genes and the frequency of tumor initiation in the two-stage Sencar mouse model. To this end, we monitored the effects of treatment of mice with diesel exhaust, benzo[a]pyrene (BP), dibenzo[a,l]pyrene (DBP), or a combination of diesel exhaust with either carcinogenic PAH. The applied diesel particulate matter (SRM(1975)) altered the tumor initiating potency of DBP: a statistically significant decrease in overall tumor and carcinoma burden was observed following 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), compared with DBP exposure alone. From those mice that were treated at the beginning of the observation period with 2 nmol DBP all survivors developed tumors (9 out of 9 animals, 100%). Among all tumors counted at the end, nine carcinomas were detected and an overall tumor incidence of 2.6 tumors per tumor-bearing animal (TBA) was determined. By contrast, co-treatment of DBP with 50mg SRM(1975) led to a tumor rate of only 66% (19 out of 29 animals), occurrence of only three carcinomas in 29 animals and an overall rate of 2.1 tumors per TBA (P=0.04). In contrast to the results with DBP, the tumor incidence induced by 200 nmol BP was found slightly increased when co-treatment with SRM(1975) occurred (71% vs. 85% after 25 weeks). Despite this difference in tumor incidence, the numbers of carcinomas and tumors per TBA did not differ statistically significant between both treatment groups possibly due to the small size of the BP treatment group. Since bioactivation of DBP, but not BP, predominantly depends on CYP1B1 enzyme activity, SRM(1975) affected PAH-induced carcinogenesis in an antagonistic manner when CYP1B1-mediated bioactivation was required. The explanation most likely lies in the much stronger inhibitory effects of certain PAHs present in diesel exhaust on CYP1B1 compared to CYP1A1. In the present study we also found molecular markers such as highly elevated AKR1C21 and TNFRSF21 gene expression levels in tumor tissue derived from animals co-treated with SRM(1975) plus DBP. Therefore we validate microarray data as a source to uncover transcriptional signatures that may provide insights into molecular pathways affected following exposure to environmental complex mixtures such as diesel exhaust particulates.


Subject(s)
Carcinogens/toxicity , DNA Damage , Particulate Matter/toxicity , Polycyclic Aromatic Hydrocarbons/toxicity , Skin Neoplasms/chemically induced , Vehicle Emissions/toxicity , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Benzo(a)pyrene/toxicity , Benzopyrenes/toxicity , Cell Transformation, Neoplastic/chemically induced , Cell Transformation, Neoplastic/metabolism , Cytochrome P-450 CYP1A1/metabolism , Cytochrome P-450 CYP1B1 , DNA Adducts/metabolism , Mice , Mice, Inbred SENCAR , Polycyclic Aromatic Hydrocarbons/metabolism , Skin Neoplasms/metabolism , Tetradecanoylphorbol Acetate/pharmacology
2.
Toxicol Sci ; 95(1): 63-73, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17060372

ABSTRACT

The polycyclic aromatic hydrocarbons (PAHs) benzo[a]pyrene (B[a]P) and dibenzo[a,l]pyrene (DB[a,l]P) are well-studied environmental carcinogens, however, their potency within a complex mixture is uncertain. We investigated the influence of urban dust particulate matter (UDPM) on the bioactivation and tumor initiation of B[a]P and DB[a,l]P in an initiation-promotion tumorigenesis model. SENCAR mice were treated topically with UDPM or in combination with B[a]P or DB[a,l]P, followed by weekly application of the promoter 12-O-tetradecanoylphorbol-13 acetate. UDPM exhibited weak tumor-initiating activity but significantly delayed the onset of B[a]P-induced tumor initiation by two-fold. When cotreated with UDPM, DB[a,l]P-treated animals displayed no significant difference in tumor-initiating activity, compared with DB[a,l]P alone. Tumor initiation correlated with PAH-DNA adducts, as detected by (33)P-postlabeling and reversed-phase high-performance liquid chromatography. Induction of cytochrome P450 (CYP)1A1 and 1B1 proteins was also detected following UDPM treatment or cotreatment with B[a]P or DB[a,l]P, indicating PAH bioactivation. Further genotoxicity analyses by the comet assay revealed that cotreatment of UDPM plus B[a]P or DB[a,l]P resulted in increased DNA strand breaks, compared with PAH treatment alone. The metabolizing activities of CYP1A1 and CYP1B1, as measured by the 7-ethoxyresorufin O-deethylation (EROD) assay, revealed that UDPM noncompetitively inhibited CYP1A1 and CYP1B1 EROD activity in a dose-dependent manner. Overall, these data suggest that components within complex mixtures can alter PAH-induced carcinogenesis by inhibiting CYP bioactivation and influence other genotoxic effects, such as oxidative DNA damage. These data further suggest that in addition to the levels of potent PAH, the effects of other mixture components must be considered when predicting human cancer risk.


Subject(s)
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Carcinogens/toxicity , Cytochrome P-450 CYP1A1/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Particulate Matter/pharmacology , Polycyclic Aromatic Hydrocarbons/toxicity , Skin Neoplasms/prevention & control , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Benzo(a)pyrene/metabolism , Benzo(a)pyrene/toxicity , Benzopyrenes/metabolism , Benzopyrenes/toxicity , Carcinogens/metabolism , Cell Transformation, Neoplastic/drug effects , Complex Mixtures/toxicity , Cytochrome P-450 CYP1A1/metabolism , Cytochrome P-450 CYP1B1 , DNA Adducts/metabolism , DNA Damage , DNA, Neoplasm/drug effects , DNA, Neoplasm/metabolism , Dust , Enzyme Induction/drug effects , Mice , Mice, Inbred SENCAR , Oxazines/metabolism , Polycyclic Aromatic Hydrocarbons/metabolism , Risk Assessment , Skin Neoplasms/chemically induced , Skin Neoplasms/enzymology , Time Factors , United States , Urban Health
3.
Toxicol Sci ; 88(2): 358-66, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16162842

ABSTRACT

Humans are exposed to complex mixtures of polycyclic aromatic hydrocarbons in the atmosphere. We examined the long term effects of a standard reference material (SRM) 1649a over time on the metabolic activation and DNA adduct formation by two carcinogenic PAHs, benzo[a]pyrene (BP) and dibenzo[a,l]pyrene (DBP) in the human mammary carcinoma derived cell line MCF-7. PAH-DNA adduct analysis, cytochrome P450 (CYP) enzyme activity, CYP1A1 and CYP1B1 protein expression were determined in cells treated with SRM 1649a alone or SRM 1649a with either BP or DBP for 24 to 120 h. Averaging over time, significantly higher levels of DNA adducts were observed in cells treated with BP or DBP alone than in co-treatments with SRM 1649a and BP or DBP. Ethoxyresorufin O-deethylase assay indicated a significant increase in activity in cells treated with BP alone and co-treated with SRM1649a in comparison to other treatment groups. Induction of CYP1A1 and CYP1B1 protein expression was observed by immunoblots in cells treated with BP alone or in co-treatments of SRM 1649a and BP or DBP. These data demonstrate the influence of the components of SRM 1649a in inhibiting the activation of BP or DBP by CYP enzymes in the formation of DNA adducts. It also suggests that the carcinogenic activity of PAH within a complex mixture may vary with composition and activation of the components present in the complex mixture.


Subject(s)
Benzo(a)pyrene/pharmacokinetics , Benzopyrenes/pharmacokinetics , Breast Neoplasms/metabolism , Carcinogens/pharmacokinetics , Complex Mixtures/pharmacokinetics , Dust , Aryl Hydrocarbon Hydroxylases/biosynthesis , Benzo(a)pyrene/toxicity , Benzopyrenes/toxicity , Biotransformation , Breast Neoplasms/drug therapy , Carcinogens/toxicity , Cell Line, Tumor , Complex Mixtures/toxicity , Cytochrome P-450 CYP1A1/biosynthesis , Cytochrome P-450 CYP1B1 , DNA/drug effects , DNA/metabolism , DNA Adducts/biosynthesis , DNA Adducts/drug effects , Drug Combinations , Humans , Microsomes/drug effects , Microsomes/enzymology , Urban Health
4.
Cancer Res ; 65(4): 1251-8, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15735009

ABSTRACT

Human exposures to polycyclic aromatic hydrocarbon (PAH) occur in complex mixtures. Here, gene expression patterns were investigated using standard reference material (SRM) 1649a (urban dust). MCF-7 cells were exposed to SRM 1649a alone or SRM 1649a with either benzo[a]pyrene (BP) or dibenzo[a,l]pyrene (DBP) for 24 hours. Global analyses of the gene expression data revealed alterations of 41 RNA transcripts with at least 2-fold change (signal log ratio /= 1) in response to SRM 1649a exposure. Increase in expression of cytochrome P450 (CYP) genes was observed in response to BP exposure (CYP1A1 and CYP1B1; signal log ratio of 4.7 and 2.5, respectively). An additive induction of CYP1A1 and CYP1B1 was observed with cotreatment of SRM 1649a and BP. On the contrary, no change in gene expression of CYP1A1 and CYP1B1 was observed when the cells were exposed to DBP. Furthermore, to study the effect of complex PAH mixtures on the metabolic activation of carcinogenic PAH to DNA-binding derivatives and to relate this with gene expression studies, PAH-DNA adduct formation was determined. SRM 1649a decreased the total level of BP-DNA adducts in comparison with BP alone. No significant difference in adduct levels was observed in response to either DBP alone or in combination with SRM 1649a. These results provide a transcriptional signature for chemical carcinogen exposure; in addition, they suggest a major factor in carcinogenic activity of PAH within complex mixtures is their ability to promote or inhibit the activation of carcinogenic PAH by the induction of CYP enzymes.


Subject(s)
Benzo(a)pyrene/pharmacology , Benzopyrenes/pharmacology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Dust , Gene Expression/drug effects , Apoptosis/genetics , Benzo(a)pyrene/chemistry , Benzo(a)pyrene/pharmacokinetics , Benzopyrenes/chemistry , Benzopyrenes/pharmacokinetics , Biotransformation , Breast Neoplasms/chemically induced , Breast Neoplasms/enzymology , Carcinogens/pharmacokinetics , Carcinogens/pharmacology , Cell Cycle/genetics , Cell Growth Processes/genetics , Cell Line, Tumor , Cytochrome P-450 Enzyme System/biosynthesis , Cytochrome P-450 Enzyme System/genetics , DNA Adducts/biosynthesis , DNA Damage , DNA Repair/genetics , Humans , Isoenzymes
SELECTION OF CITATIONS
SEARCH DETAIL
...